WARRINGTON, PA — Windtree Therapeutics, Inc. (NasdaqCM: WINT) has announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. patent application number 18/150,870. The patent protects the company’s istaroxime intravenous formulation, specifically targeting the treatment of acute heart failure (AHF).
A Step Forward in Heart Failure Treatment
Acute heart failure is a severe condition affecting millions globally and imposing a substantial strain on healthcare systems. Windtree CEO Jed Latkin emphasized the importance of advancing innovative therapies, noting that this Notice of Allowance represents a meaningful milestone in expanding intellectual property (IP) protections for istaroxime in the U.S.
“The potential of istaroxime to address an unmet need in AHF treatment is truly exciting,” Latkin stated, signaling the company’s focus on addressing the long-standing challenges in managing this critical condition.
Istaroxime’s Dual-Mechanism of Action
Istaroxime is a first-in-class therapy designed to enhance both systolic (pumping) and diastolic (relaxation) heart function. Its dual-mechanism of action combines positive inotropic effects achieved through Na+/K+-ATPase inhibition with enhanced myocardial relaxation facilitated by SERCA2a calcium pump activation. This complementary approach aims to improve cardiac contractility while promoting calcium reuptake, reducing stress on the heart.
Clinical data from multiple Phase 2 trials have demonstrated that intravenous istaroxime significantly improves cardiac function and blood pressure without raising heart rate or triggering rhythm disturbances, making it a promising option for patients facing early cardiogenic shock or acute decompensated heart failure.
Enhancing IP Strategies and Treatment Options
With the issuance of this Notice of Allowance, Windtree strengthens its IP portfolio surrounding istaroxime. This development lays the groundwork for advancing the drug toward regulatory approval and potential commercialization.
As the healthcare industry continues to grapple with the costs and complexities of AHF management, Windtree’s progress with istaroxime serves as a significant step toward providing new hope for patients and solutions for clinicians.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.